Axsome Therapeutics, Inc.

NASDAQ:AXSM

Biotechnology

Healthcare
$134.00 +0.10%

+$0.25 today

Market cap
$7.05B
Beta
0.60
P/E (TTM)
-68.6
EPS (TTM)
-$3.68
52W Low $96.09High $257.93

Volume 0.74M

Average 0.72M

AXSM Research & Development

Spending on developing new products, technologies, and improvements to existing offerings.

Axsome Therapeutics, Inc.NASDAQ: AXSM

Research & Development · Q2 FY2026 · quarter ended Jun 2026

Research & development declines year over year

Q2 FY2026 research & development of $46.23M fell 6.7% year over year, behind the -3.5% change in trailing-twelve-month research & development. Sequentially, it fell 12.2% from the prior quarter. Over 3 fiscal years it compounded at +46.8% a year.

Context

  • Research & development amounted to 28.7% of revenue in FY2025, down 19.8 pp from a year earlier.
  • Research & development increased in 2 of the last 3 fiscal years.

What to watch

Whether quarterly growth recovers from -6.7% toward the trailing-twelve-month pace of -3.5%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterJun 2026
$46.23M-12.2% QoQ
Last fiscal yearDec 2025
$183.28M-2.0% YoY
LTMJun 2026
$187.86M-3.5% YoY
Research & Development past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-6.7%——
1 year-2.0%——
3-year CAGR+46.8%——
5-year CAGR——
10-year CAGR——

Research & Development history

USD · from the income statement

Latest · FY2025
183.28M USD
Year-over-year change
-2.0%
4-year CAGR
+33.3%

Research & Development vs competitors

How AXSM compares with its peers on the latest reported figures

  • AXSM's LTM Jun 2026 research & development of $187.86M is the 6th highest of the 11 companies compared; the peer median is $229.46M.
  • Its year-over-year change of -3.5% is the 7th highest of 11, against a peer median of +17.9%.
  • Research & development amounts to 24.2% of revenue for AXSM, versus a peer median of 33.3%.
AXSM Competitors Peer median
Research & Development for AXSM and competitors
Company Period LTM YoY 3-year CAGR% of revenue
NBIXNeurocrine Biosciences, Inc.LTM Sep 2026$1.23B +30.7%+29.9%33.3%
JAZZJazz Pharmaceuticals plcLTM Sep 2026$623.61M -26.8%+9.9%13.2%
DNLIDenali Therapeutics Inc.LTM Jun 2026$400.72M -3.9%+5.3%11118.8%
XENEXenon Pharmaceuticals Inc.LTM Sep 2026$371.08M +36.1%+41.7%—
PRAXPraxis Precision Medicines, Inc.LTM Sep 2026$289.11M +17.6%+19.9%—
AXSMAxsome Therapeutics, Inc.LTM Jun 2026$187.86M -3.5%+46.8%24.2%
DFTXDefinium Therapeutics, Inc.LTM Sep 2026$169.81M +60.3%+48.2%—
NMRANeumora Therapeutics, Inc. Common StockLTM Mar 2026$162.51M -21.6%+18.9%—
SUPNSupernus Pharmaceuticals, Inc.LTM Jun 2026$126.09M +18.1%+12.5%15.2%
RAPPRapport Therapeutics, Inc. Common StockLTM Mar 2026$107.93M +58.7%+118.3%539.7%
AVXLAnavex Life Sciences Corp.LTM Dec 2025$31.8M -27.0%-0.3%—
Peer median (excluding AXSM) $229.46M+17.9%+19.4%33.3%

Competitors are the stored peer set for AXSM. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue050.04M270.6M385.69M638.5M
Cost of Revenue05.2M26.07M33.3M47.48M
Gross Profit044.84M244.54M352.39M591.02M
Gross Margin—89.6%90.4%91.4%92.6%
Research & Development58.06M57.95M97.94M187.08M183.28M
Selling, General & Admin66.65M159.25M323.12M411.36M570.6M
Operating Expenses124.71M224.64M476.36M632.95M760.25M
Depreciation & Amortization76K4.4M6.83M7.96M9.06M
EBITDA(124.63M)(175.4M)(224.99M)(272.6M)(168.08M)
EBITDA Margin—-350.5%-83.1%-70.7%-26.3%
Operating Income(124.71M)(179.8M)(231.83M)(280.56M)(169.24M)
Operating Margin—-359.3%-85.7%-72.7%-26.5%
Interest Income00009.37M
Interest Expense5.7M7.34M6.45M6.57M6.56M
Other Income / Expenses(5.7M)(7.34M)(6.45M)(6.57M)(14.47M)
Income Before Tax(130.4M)(187.13M)(238.28M)(287.13M)(183.7M)
Pre-Tax Margin—-374.0%-88.1%-74.4%-28.8%
Income Tax Expense00960K85K(530K)
Net Income(130.4M)(187.13M)(239.24M)(287.22M)(183.17M)
Net Margin—-374.0%-88.4%-74.5%-28.7%
EPS (Basic)(3.47)(4.60)(5.27)(5.99)(3.68)
EPS (Diluted)(3.47)(4.60)(5.27)(5.99)(3.68)
Weighted Avg Shares37.62M40.66M45.43M47.91M49.75M
Weighted Avg Shares (Diluted)37.62M40.66M45.43M47.91M49.75M

Axsome Therapeutics, Inc.

NASDAQ:AXSM

Intrinsic Alpha fair value

Locked

Current Price

$134.00

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.